Clinical Trial Update: A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating adverse events and changes in disease activity after intravenous or subcutaneous lutikizumab in adults with active ulce…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Lutikizumab (lutikizumab)

Snippet

Sponsor: AbbVie | Conditions: Ulcerative Colitis | Phase 2 | Status: ACTIVE_NOT_RECRUITING